EXACT Sciences Corporation has announced promising results from the Beta-CORRECT clinical validation study, which will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study validates the performance of the Oncodetect™ test, a tumor-informed molecular residual disease $(MRD.AU)$ test, in predicting cancer recurrence specifically in stage II-IV colorectal cancer patients. This confirmation of the test's clinical utility supports its role in aiding treatment and surveillance decisions for clinicians and patients. Additionally, Exact Sciences is preparing to launch a next-generation version of the Oncodetect test in 2026, powered by the Broad Institute's MAESTRO technology, which will offer ultra-low limits of detection and the ability to track up to 5,000 patient-specific variants. This advancement aims to enhance sensitivity and expand the clinical utility of cancer detection and monitoring.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.